Close this search box.
Follow us




Diabetes is a chronic, metabolic disease that affects how your body turns food into energy, in which carbohydrate, protein, and fat metabolism is impaired.

This metabolic health disorder characterized by elevated levels of blood glucose due to unstable insulin secretion, insulin resistance secretion, or both; in long-term leads to severe damage to the heart, blood vessels, nerves, eyes and kidneys. The most common type especially in adults is a diabetes mellitus type2, which occurs when the body doesn’t make enough insulin or becomes resistant to insulin. The prevalence of type 2 diabetes has risen remarkably in countries of all income levels in the last decades. Type 1 diabetes which formerly known as insulin-dependent diabetes or juvenile diabetes is a long-term health problem in which little or no insulin is produced by pancreas.

There is something about 422 million diabetic patients worldwide, most of them living in low-and middle-income countries, and leads to 1.5million deaths each year. The most considerable point is that in the last decades the number of diabetic patients and the prevalence of diabetes have been steadily increasing. According to prevalence incidence of diabetes in adults aged 18 years and older in 2014 which was around 8.5 percent globally, numerous estimates predict that the number of diabetic patients globally will be risen from 422 million to 642 million by 2040. The highest prevalence of diabetes compared to other WHO regions was belonged to the Eastern Mediterranean Region (EMRO), which was 13.7% in 2014.

Hence, one of Parsian’s fields of activity is research and development in diabetes to manufacture active pharmaceutical ingredients (API) and Granules of diabetes medicines with the highest global standards to help patients having diabetes to be cured in a better way by the latest guidelines and with the lowest adverse effects.



Sitagliptin phosphate monohydrate


Cas No: 654671-77-9

Mechanism Of Action: Sitagliptin functions by stimulating insulin production and reducing the excessive production of glucose in the liver. It achieves this by prolonging the



Cas No: 668270-12-0

Mechanism Of Action: Linagliptin is a competitive, reversible DPP-4 inhibitor. Inhibition of this enzyme slows the breakdown of GLP-1 and glucose-dependant insulinotropic polypeptide (GIP). GLP-1

Dapagliflozin propandiol.H2O


Cas No: 960404-48-2

Mechanism Of Action: Dapagliflozin inhibits the sodium-glucose contransporter 2(SGLT2) which is primarily located in the proximal tubule of the nephron. SGLT2 facilitates 90% of glucose



Cas No: 864070-44-0

Mechanism Of Action: The vast majority of glucose filtered through the glomerulus is reabsorbed within the proximal tubule, primarily via SGLT2 (sodium-glucose linked co-transporter-2) which